S1159
Clinical - Urology
ESTRO 2026
are listed in table1.
ROC-analysis showed a PSA-value of 0.55ng/mL (AUC=0.72; sensitivity-84%;specificity-60%) and DT-PSA 9.2months (AUC=0.60; sensitivity-89%;specificity-37%) for predicting positive-PET findings. In patients with positive ¹⁸ F-DCFPyL-PET/CT findings, therapeutic-
Positive ¹⁸ F-DCFPyL-PSMA-PET/CT findings were observed in 53% of patients. Median-PSA prior to imaging was 0.59ng/mL (0.29–1.0; p=0.004) and median DT-PSA was 7 months (3–9; p=0.005). DR increased with PSA level: 31.3% (< 0.5ng/mL), 60% (0.5- 1.0ng/mL), and 77.8% (>1ng/mL). Regarding DT-PSA, DR were 61.5%, 50%, and 26.7% for <6, 6–12, and >12months, respectively (p<0.005). DR also correlated with ISUP-risk-group (24%, 59%, and 68.4% for groups 1–2,3, and 4–5; p< 0.02). A total of 90 lesions were detected: 21 local-recurrences, 48 LN, 18 bone, and 3 visceral-metastases. The DR by location was 22.2% for local-recurrence, 51.1% LN-involvement, 20% bone and 6.7% for visceral-involvement. Additionally, positive findings by location were analyzed in relation to PSA-levels and DT-PSA (Figure 1).
strategies were modified in 84.4% of cases (p<0.001). Prior to imaging, all patients were
candidates for salvage/adjuvant radiotherapy, ADT or observation. Based on PSMA-PET-results, treatment was individualized: targeted-radiotherapy to pelvic-LN with/without dose-escalation, SBRT to PSMA-avid- lesions, or intensified prostate-bed-radiotherapy. Due to detection of extra-pelvic-nodal, bone, or visceral- metastases, 42.3% of patients were referred for systemic-therapy with androgen-receptor-signaling- inhibitors (ARSIs). Figure-2
Made with FlippingBook - Share PDF online